T6654

Ticlopidine hydrochloride

Name: Ticlopidine hydrochloride
Brand: SIAL
Price: 42.1 USD
Availability: InStock

analytical standard, for drug analysis

Synonym(s):

5-(o-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine

Slide 1 of 1

Select a Size

1 G

$42.10

Available to ship TODAYDetails

One Time Order

Request a Bulk Order

Subscriptions are currently unavailable.

About This Item

Empirical Formula (Hill Notation):

C₁₄H₁₄ClNS · HCl

CAS Number:

53885-35-1

Molecular Weight:

300.25

NACRES:

NA.24

PubChem Substance ID:

329826850

UNSPSC Code:

41116107

EC Number:

258-837-4

MDL number:

MFCD00079606

Key Documents

View All Documentation

Product Name

Ticlopidine hydrochloride, analytical standard, for drug analysis

InChI key

MTKNGOHFNXIVOS-UHFFFAOYSA-N

InChI

1S/C14H14ClNS.ClH/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14;/h1-4,6,8H,5,7,9-10H2;1H

SMILES string

Cl.Clc1ccccc1CN2CCc3sccc3C2

assay

≥99%

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

format

neat

Quality Level

100

Gene Information

human ... P2RY12(64805)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Chemistry

Analytical Chromatography

Chromatography Standards

Controlled Substances & Illicit Drug Standards

Reference Materials

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item	I114	B5274	M187
Supelco T6654 Ticlopidine hydrochloride	Supelco I114 p-Iodoclonidine hydrochloride	Supelco B5274 Bupivacaine hydrochloride monohydrate	Supelco M187 (+)-3-Methoxymorphinan hydrochloride
application(s) forensics and toxicology pharmaceutical (small molecule) veterinary	application(s) forensics and toxicology pharmaceutical (small molecule) veterinary	application(s) forensics and toxicology pharmaceutical (small molecule) veterinary	application(s) forensics and toxicology pharmaceutical (small molecule) veterinary
technique(s) HPLC: suitable, gas chromatography (GC): suitable	technique(s) HPLC: suitable, gas chromatography (GC): suitable	technique(s) HPLC: suitable, gas chromatography (GC): suitable	technique(s) HPLC: suitable, gas chromatography (GC): suitable
Quality Level 100	Quality Level 100	Quality Level 100	Quality Level 100
grade analytical standard, for drug analysis	grade analytical standard, for drug analysis	grade analytical standard, for drug analysis	grade analytical standard, for drug analysis
assay ≥99%	assay -	assay ≥99%	assay -
format neat	format neat	format neat	format neat

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Ticlopidine hydrochloride has been used as an analytical standard to investigate the developmental toxicity and teratogenic potential of ticlopidine in Xenopus laevis embryos and human endothelial cells using a frog embryo teratogenesis assay-Xenopus (FETAX) and blood and lymph vessel formation assay.[1]

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Characterization of ticlopidine-induced developmental and teratogenic defects in Xenopus embryos and human endothelial cells.

Park SM, et al.

Chemico-Biological Interactions, 240, 172-178 (2015)

Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).

Peter Damman et al.

The American journal of cardiology, 113(1), 64-69 (2013-10-31)

Large real-world registry data are important for understanding the current use and outcomes of novel therapies. The aim of this study was to assess treatment patterns and outcomes in patients who underwent percutaneous coronary intervention (PCI) with prasugrel or clopidogrel.

CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.

Thomas O Bergmeijer et al.

American heart journal, 168(1), 16-22 (2014-06-24)

In patients with ST-segment elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (pPCI), the use of dual antiplatelet therapy is essential to prevent atherothrombotic complications. Therefore, patients are treated with acetylsalicylic acid and clopidogrel, prasugrel, or ticagrelor. Clopidogrel

Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial.

Jan H Cornel et al.

American heart journal, 168(1), 76-87 (2014-06-24)

To further explore the impact of smoking on antiplatelet activity and treatment response, we evaluated time-dependent relationships between smoking status with on-treatment platelet reactivity and clinical outcomes for prasugrel vs. clopidogrel in patients with acute coronary syndromes managed medically without

Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.

Colin P Derdeyn et al.

Lancet (London, England), 383(9914), 333-341 (2013-10-31)

Early results of the Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis trial showed that, by 30 days, 33 (14·7%) of 224 patients in the stenting group and 13 (5·8%) of 227 patients in the medical

View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service